Expertise in
11
conditions

Dr. Tejas S. Patil

Oncology
University Of Colorado Hospital
1665 Aurora Ct, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
University Of Colorado Hospital
1665 Aurora Ct, 
Aurora, CO 

Overview

Tejas Patil is an Oncologist practicing medicine in Aurora, Colorado.

Dr. Patil is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

He is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 5 clinical trials. Dr. Patil is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CO

Hospital Affiliations

Uchealth Highlands Ranch Hospital
University Of Colorado Hospital Authority
Uchealth Broomfield Hospital
Longs Peak Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

University of Colorado Hospital
1665 Aurora Ct, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations
Enrollment Status: Recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Biological
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug, Procedure
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase 1/2 Open-Label Study To Determine a Central Nervous System (CNS) Dose and Schedule Of Tepotinib Alone Or In Combination With Other Relevant Tyrosine Kinase Inhibitors (TKIs) In Adult Participants With MET-Driven NSCLC
A Phase 1/2 Open-Label Study To Determine a Central Nervous System (CNS) Dose and Schedule Of Tepotinib Alone Or In Combination With Other Relevant Tyrosine Kinase Inhibitors (TKIs) In Adult Participants With MET-Driven NSCLC
Enrollment Status: Terminated
Publish Date: October 18, 2023
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 1/Phase 2
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors
Enrollment Status: Withdrawn
Publish Date: September 21, 2022
Intervention Type: Diagnostic test
View 4 Less Clinical Trials

81 Total Publications

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 17, 2026
Similar Doctors
Expertise in
66
conditions
Expertise in
66
conditions
Referral may be required

Rocky Mountain Cancer Centers

1700 S Potomac St, 
Aurora, CO 
 (4.0 miles away)
303-418-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Burke is an Oncologist practicing medicine in Aurora, Colorado. Dr. Burke is highly rated in 66 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Classical Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Nephrectomy. Dr. Burke is board certified in American Board Of Internal Medicine. Dr. Burke is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.1 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Elias is an Oncologist practicing medicine in Aurora, Colorado. Dr. Elias is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Adult Soft Tissue Sarcoma, Liposarcoma, and Inflammatory Breast Cancer. Dr. Elias is currently accepting new patients.

Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (0.2 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rajeev Vibhakar is a Hematologist and an Oncologist practicing medicine in Aurora, Colorado. Dr. Vibhakar is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Gliomatosis Cerebri. Dr. Vibhakar is currently accepting new patients.

Frequently Asked Questions about Dr. Tejas S. Patil

How do I make an appointment with Dr. Tejas S. Patil?

You can book an appointment with Dr. Tejas S. Patil by calling their office at 720-848-9264. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tejas S. Patil a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tejas S. Patil is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tejas S. Patil specialize in?

While Dr. Tejas S. Patil is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and EGFR Positive Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Tejas S. Patil participate in research or clinical trials?

Yes. Dr. Tejas S. Patil has published 81 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Tejas S. Patil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tejas S. Patil accept my insurance?

Dr. Tejas S. Patil accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 720-848-9264 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patil's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile